We suggest it is supportive to take delicate individualized combination therapy including ACE inhibitor and inotropic agents for cardiomyopathy in DMD patients with EF < 45%, rather than usual heart failure therapy. This evidence concerns the gene ACE and Duchenne muscular dystrophy.